JOHNSON & JOHNSON
CIK 200406 · View on SEC EDGAR ↗
- Portfolio value
- $652.4M
- Positions
- 16
- As of
- March 31, 2026 Data as of Q1 2026
#2,982 of 8,643 by 13F value · top 34.5%
Portfolio value QoQ: +17.5% 13F does not disclose cash
- Top 10 holdings weight
- 98.41%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 11
- Effective number of positions
- 4.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.22% Est. buys $11,842,506 · sells $1,561,190
Median holding: 6.0 quarters Tracked Q4 2024–Q2 2026 · 60.0% still held
- New positions
- 1
- Increased
- 0
- Decreased
- 0
- Closed
- 2
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Sector breakdown
Healthcare
98.5%
Other/Unmapped
1.5%
Full portfolio 15 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $300,220,852 | 37.59% | 2,449,183 | $42,076,964 | |||
| NBTX Nanobiotix S.A. - ADSs | $212,017,863 | 26.55% | 5,623,816 | $38,410,663 | |||
| MGTX MeiraGTx Holdings plc - Ordinary Shares | $89,720,775 | 11.23% | 6,641,064 | $32,209,161 | |||
| RAPP Rapport Therapeutics, Inc. - Common Stock | $74,360,823 | 9.31% | 1,784,517 | $18,523,286 | |||
| CTNM Contineum Therapeutics, Inc. - Common stock | $32,438,645 | 4.06% | 1,979,173 | $6,590,646 | |||
| LEGN Legend Biotech Corporation - American Depositary Shares | $23,525,244 | 2.95% | 814,586 | $8,789,383 | |||
| CVRX CVRx, Inc. - Common Stock | $20,687,786 | 2.59% | 4,024,861 | $-17,387,399 | |||
| XNCR Xencor, Inc. - Common Stock | $12,043,798 | 1.51% | 748,062 | $3,022,170 | |||
| Unknown issuer (CUSIP: 15675D103) | $11,842,506 | 1.48% | 53,586 | Up ×1 | |||
| FATE Fate Therapeutics, Inc. - Common Stock | $9,123,473 | 1.14% | 3,379,064 | $5,068,596 | |||
| PRCT PROCEPT BioRobotics Corporation - Common Stock | $8,082,263 | 1.01% | 357,939 | $-869,791 | |||
| NMRA Neumora Therapeutics, Inc. - Common Stock | $3,144,057 | 0.39% | 1,849,445 | $-462,361 | |||
| VOR Vor Biopharma Inc. - Common Stock | $989,206 | 0.12% | 53,732 | $30,627 | |||
| LAB Standard BioTools Inc. - Common Stock | $256,655 | 0.03% | 311,967 | $-30,136 | |||
| ACET Adicet Bio, Inc. - Common Stock | $196,811 | 0.02% | 22,779 | $41,686 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 15675D103) | $11,842,506 | 53,586 | 1.48% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| PTGX | Price move only | +0 | +$42.1M |
| NBTX | Price move only | +0 | +$38.4M |
| MGTX | Price move only | +0 | +$32.2M |
| RAPP | Price move only | +0 | +$18.5M |
| CVRX | Price move only | +0 | -$17.4M |
| LEGN | Price move only | +0 | +$8.8M |
| CTNM | Price move only | +0 | +$6.6M |
| FATE | Price move only | +0 | +$5.1M |
| XNCR | Price move only | +0 | +$3.0M |
| PRCT | Price move only | +0 | -$870K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| ARWR | Dec. 31, 2025 | 247,598 | $8,539,655 | 33.6% |
| VORXXXX | Dec. 31, 2025 | 53,732 | $2,617,823 | No longer tracked |
| LYEL | March 31, 2026 | 54,887 | $1,689,422 | -16.6% |
| RLYB | June 30, 2026 | 152,901 | $1,371,522 | 7.2% |
| LYELXXXX | Sept. 30, 2025 | 41,165 | $368,015 | No longer tracked |
| NNOX | June 30, 2026 | 83,554 | $189,668 | -20.8% |
| PHGE | Dec. 31, 2025 | 96,866 | $50,855 | No longer tracked |
| SENS | Dec. 31, 2025 | 54,621 | $23,804 | 58.5% |